Microbot Medical® to Participate at the 38th Annual Roth Conference

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) will present at the 38th Annual Roth Conference March 22-24, 2026, with a live webcast fireside Q&A on March 23, 2026 at 4:00 pm PT. CEO Harel Gadot will discuss LIBERTY commercial progress, limited market release traction, and plans for a full market release in April 2026 at SIR.

The webcast is available via the company’s Investors site and the presentation aims to showcase product differentiation, physician safety benefits, and upcoming commercialization steps.

News Market Reaction – MBOT

+1.10%

1 alert

+1.10% News Effect

On the day this news was published, MBOT gained 1.10%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 38th Annual Fireside Q&A time: 4:00 pm PT Conference dates: March 22–24, 2026 +5 more

8 metrics

Conference edition 38th Annual Roth Annual Growth Conference

Fireside Q&A time 4:00 pm PT Live webcast on March 23, 2026

Conference dates March 22–24, 2026 Roth Annual Growth Conference schedule

Full market release timing April 2026 Planned full market release of LIBERTY at SIR conference

Limited market release start Late 2025 Commencement of LIBERTY limited market release

Current share price $2.73 Price before Roth conference news

52-week range $1.35 – $4.67 MBOT 52-week low and high

Market cap $180,655,138 Equity value prior to the announcement

Market Reality Check

Price: $2.64 Vol: Volume 1,277,879 is below...

low vol

$2.64 Last Close

Volume Volume 1,277,879 is below the 20-day average of 2,195,653, suggesting no heavy trading ahead of the event. low

Technical Price $2.73 is trading above the 200-day MA at $2.58, indicating a modest bullish backdrop pre-announcement.

Peers on Argus

MBOT gained 1.49% with below-average volume, while scanner peers were mixed: OSU...

2 Up 1 Down

MBOT gained 1.49% with below-average volume, while scanner peers were mixed: OSUR up 3.83%, PDEX up 2.74%, and UTMD down 3.14%. Limited peer alignment points to a stock-specific reaction rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Conference participation	Positive	+2.9%	First-time Oppenheimer conference appearance to showcase LIBERTY growth drivers.
Mar 04	Policy alignment	Positive	+2.5%	Endorsed AMA radiation-safety policy highlighting LIBERTY’s exposure reduction data.
Mar 03	Operational update	Positive	-3.6%	Confirmed operational stability and U.S. commercialization amid geopolitical events.
Feb 24	Hospital adoption	Positive	+23.9%	Tampa General Hospital became first Florida adopter post-FDA clearance.
Feb 19	Innovation showcase	Positive	+2.4%	LIBERTY featured at Surgical Disruptive Technology Summit panel on AI and robotics.

Pattern Detected

Recent news tied to LIBERTY’s commercialization and visibility has usually seen positive price reactions, with one notable divergence on a geopolitical stability update.

Recent Company History

Over the last month, MBOT has repeatedly highlighted progress and visibility for its LIBERTY Endovascular Robotic System ahead of a planned full market release at SIR in April 2026. Events included conference participation at Oppenheimer (Mar 19, 2026), alignment with AMA radiation-safety policy, confirmation of operational stability during geopolitical events, and a key adoption at Tampa General Hospital. These announcements generally produced positive single- to double-digit moves, framing today’s Roth conference participation as part of an ongoing commercial rollout narrative.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active S-3/A shelf filed on 2025-10-28, with effectiveness pending under Section 8(a) of the Securities Act. The shelf has been used in 2 prior 424B3 filings, indicating some prior access to registered capital but no disclosed remaining capacity in the provided data.

Market Pulse Summary

This announcement centers on Microbot Medical’s participation in the Roth conference and a fireside ...

Analysis

This announcement centers on Microbot Medical’s participation in the Roth conference and a fireside Q&A on March 23, 2026, continuing a series of events spotlighting its LIBERTY robotic system ahead of full market release in April 2026. Recent history shows consistent messaging around commercial rollout and operational stability. Investors may focus on additional adoption metrics, commercialization details, and any updates shared during the webcast to gauge the trajectory of LIBERTY’s market penetration.

Key Terms

endovascular, peripheral endovascular procedures, robotic system, FDA cleared

4 terms

endovascular medical

"LIBERTY® Endovascular Robotic System, announced that it will participate..."

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

peripheral endovascular procedures medical

"robotic system for peripheral endovascular procedures, and it is designed..."

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

robotic system technical

"LIBERTY® Endovascular Robotic System, announced that it will participate..."

A robotic system is a combination of machines, sensors and software that carries out physical tasks with various levels of independence — from guided arms on factory floors to medical robots that assist surgeons. For investors, robotic systems matter because they can lower labor costs, boost speed and precision, or enable new products and services; like a smart, tireless worker, they can change a company’s productivity, margins and growth potential.

FDA cleared regulatory

"LIBERTY is the only FDA cleared, single-use, remotely operated robotic system..."

FDA cleared means the U.S. Food and Drug Administration reviewed a medical device and agreed it is similar enough to an already allowed product to be marketed in the United States. Think of it like a new car model using largely the same, proven parts as an earlier model — the regulator gives a green light for sales but does not imply the more extensive testing required for full approval. For investors, clearance signals regulatory access to the U.S. market and typically lowers commercialization risk compared with no clearance.

AI-generated analysis. Not financial advice.

Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in April

HINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23^rd. Mr. Gadot will highlight the Company’s recent achievements, and how LIBERTY is a unique and differentiated solution, addressing critical unmet healthcare needs, including physician safety and staffing issues.

The presentation will be a live webcast and may be accessed via the ‘Investors’ section on Microbot Medical’s website at https://ir.microbotmedical.com/. Additionally, Mr. Gadot will be meeting growth-oriented institutional investors and other interested parties on Monday, March 23^rd, through a series of pre-scheduled one-on-one meetings. Investors should reach out to their Roth sales representatives or contact mpolyviou@evcgroup.com to schedule a one-on-one meeting.

“We believe the ongoing progress and success of our limited market release, driven by multi-site customer traction and procedural diversity, has validated our strategy to support the full market release, which is on target for next month,” commented Mr. Gadot. “We believe the Roth conference is an ideal stage to showcase this commercial momentum and introduce our differentiated growth story to a diverse audience, to support our current position and future growth.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

When is Microbot Medical (MBOT) presenting at the Roth Conference and how can I watch the webcast?

Microbot Medical presents on March 23, 2026 at 4:00 pm PT with a live webcast. According to the company, the fireside Q&A will be accessible via the Investors section of Microbot Medical’s website for on-demand viewing and investor access.

What will CEO Harel Gadot cover about LIBERTY during the March 23, 2026 MBOT fireside Q&A?

The CEO will highlight recent commercial progress, customer traction, and product differentiation. According to the company, discussion will focus on limited market release results, physician safety benefits, and readiness for a planned full market release in April 2026.

What is Microbot Medical’s timeline for the LIBERTY full market release and where will it be showcased?

Microbot Medical plans a full market release of LIBERTY in April 2026 at the Society of Interventional Radiology conference. According to the company, this timing follows a limited market release begun in late 2025 to deepen market adoption.

How does Microbot Medical describe the LIBERTY system’s clinical and safety benefits in investor presentations?

The company says LIBERTY aims to reduce radiation exposure and operator physical strain during peripheral endovascular procedures. According to the company, LIBERTY is an FDA-cleared, single-use, remotely operated robotic system designed for precise vascular navigation.

How can investors schedule one-on-one meetings with Microbot Medical at the Roth Conference (MBOT)?

Investors can arrange meetings through Roth sales representatives or by contacting the provided email for scheduling. According to the company, management will hold pre-scheduled one-on-one meetings on March 23, 2026 to meet growth-oriented institutional investors.